Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and ...

Generic drugmakers in India launch affordable Semaglutide versions, targeting a $1 billion diabetes and weight loss market.

Doctors explain the differences between the Wegovy pill and injection in terms of efficacy, side effects, and more. They ...

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian ...

Following the patent expiry of semaglutide in India, leading pharma companies including Sun Pharma, Dr Reddy’s, Zydus, and ...

Zydus Lifesciences has launched Semaglutide Injection under the brand names SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided ...

Natco Pharma said the multi-dose vial format is priced around 70% lower than pen devices and nearly 90% cheaper than the innovator product, aimed at improving patient access and long-term treatment ...

March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to ...

Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as "Zydus"), an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names - ...

Sun Pharmaceutical Industries has announced the launch of its semaglutide injection in India under the brand names Noveltreat and Sematrinity, across multiple strengths for the treatment of obesity ...

Natco Pharma launches Semaglutide injection in India for type-2 diabetes, with pricing details and brand names announced.